Results 31 to 40 of about 71 (52)

Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin‐18 isoform 2 splicing variants in gastric cancer and other solid tumours

Clinical and Translational Medicine, Volume 14, Issue 6, June 2024.
Masuko Katoh, Izuma Nakayama, Zev A Wainberg, Kohei Shitara, Masaru Katoh   +4 more
wiley   +1 more source

위암에서 Fibroblast growth factor receptor 2b의 낮은 양성률과 이질적 발현 양상과의 연관성

Background: Bemarituzumab, a monoclonal antibody targeting fibroblast growth factor receptor 2b (FGFR2b), is under evaluation in phase 3 trials of gastric cancer (GC) trials. However, data on the characteristics, prognostic significance, and heterogenous
이헌우
core   +1 more source

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.

Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1-4) orchestrates fetal development and contributes to tissue and whole-body homeostasis, but can also promote tumorigenesis.
Wainberg ZA, Katoh M, Tavolari S, Katoh M., Loriot Y, Brandi G   +5 more
core   +1 more source

Trial in progress: Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102).

, 2022
Markus H. Moehler, Eric Van Cutsem, Yoon-Koo Kang, Alissa Keegan, Kohei Shitara, Elizabeth Finger, Zev A. Wainberg, Priscilla Yen   +7 more
core   +1 more source

Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101).

, 2022
Anita Zahlten-Kumeli, Kei Muro, Elizabeth Catherine Smyth, Joseph Chao, Rolando Eduardo Yanes, Sun Young Rha, Priscilla Yen   +6 more
core   +1 more source

Abstract LB539: Development of GB2102, a novel and highly differentiated anti-FGFR2b antibody for the treatment of gastric cancer

, 2022
Shuhua Han, Qinglin Du, Xueyan Yang, Fei Peng, Tiantian Zhou, James Li   +5 more
core   +1 more source

Faculty Opinions recommendation of Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

, 2023
Jaffer Ajani
core   +1 more source

Bemarituzumab

, 2020

core   +1 more source

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

, 2023
Catenacci, Daniel VT,; Rasco, Drew,; Lee, Jeeyun,; Rha, Sun Young,; Lee, Keun-Wook,; Bang, Yung Jue,; Bendell, Johanna,; Enzinger, Peter,; Marina, Neyssa,; Xiang, Hong,; Deng, Wei,; Powers, Janine,; Wainberg, Zev A,
core  

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma [PDF]

Journal of Clinical Oncology, 2020
Purpose: To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA).
Hong Xiang, Daniel V T Catenacci, Sun Young Rha   +2 more
exaly   +4 more sources